← Back to Search

Bupivacaine Liposome Injection [Exparel] for Traumatic Injury

Phase 4
Waitlist Available
Led By Chadrick R Evans, MD
Research Sponsored by Chadrick Evans
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* All patients 18 years of age or older suffering 3 or more rib fractures treated by University of Illinois College of Medicine at Peoria (UICOMP) attending or resident physicians at OSF St. Francis Medical Center (OSFMC) are potentially eligible for enrollment in the trial.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 24hours for 96hours
Awards & highlights

Summary

Management of traumatic rib fractures continues to be a challenge for trauma surgeons. Currently, many analgesic options are available to patients suffering from rib fractures. Formulations currently used for conventional intercostal nerve blocks (CINB) are relatively safe, do not require additional equipment or specialized anesthesia personnel, do not require catheter repositioning, and provide improved analgesia immediately over the aforementioned systemic therapies. A goal of these authors to introduce an additional safe option for extended local analgesia in the setting of multiple rib fractures given the inconclusive evidence supporting or refuting the current standard of care

Eligible Conditions
  • Trauma
  • Traumatic Injury
  • Acute Pain

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 24hours for 96hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 24hours for 96hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in pain relief
Secondary study objectives
Costs
ICU stay
Length of pain medication
+8 more

Trial Design

2Treatment groups
Active Control
Group I: Bupivacaine Liposome Injection [Exparel]Active Control1 Intervention
Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
Group II: Epidural 0.125% bupivicaineActive Control1 Intervention
Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury. However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician.

Find a Location

Who is running the clinical trial?

University of Illinois College of Medicine at PeoriaOTHER
14 Previous Clinical Trials
5,829 Total Patients Enrolled
Chadrick EvansLead Sponsor
OSF Healthcare SystemOTHER
30 Previous Clinical Trials
33,498 Total Patients Enrolled
~37 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top